This an accepted manuscript published in: Chemical Physics Letters. The final version can be found at: https://doi.org/10.1016/j.cplett.2021.139294 © 2021 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/

- 1 Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-
- 2 atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity
- 3 inhibition
- 4 Julia J Liang^{1,2}, Eleni Pitsillou^{1,2}, Katherine Ververis¹, Victor Guallar^{3,4}, Andrew Hung², Tom
- 5 C Karagiannis^{1,5}
- ⁶ ¹ Epigenomic Medicine, Department of Diabetes, Central Clinical School, Monash University,
- 7 Melbourne, VIC 3004, Australia
- ² School of Science, STEM College, RMIT University, VIC 3001, Australia
- ³ Barcelona Supercomputing Center, Jordi Girona 29, E-08034 Barcelona, Spain
- ⁴ ICREA, Passeig Lluís Companys 23, E-08010 Barcelona, Spain
- ⁵ Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3052,
 Australia
- 13
- 14 Keywords: Coronavirus, COVID-19, SARS-CoV-2, papain-like protease, GRL0617,
- 15 hypericin, molecular modelling
- 16 Running (short) title: SARS-CoV-2 papain-like protease inhibitors
- 17
- 18 Author for correspondence:
- 19 Tom Karagiannis, PhD
- 20 Head Epigenomic Medicine Program
- 21 Department of Diabetes
- 22 Central Clinical School
- 23 Monash University
- 24 Melbourne, VIC 3004, Australia
- 25 email: tom.karagiannis@monash.edu
- 26 phone: 61 400 857 906

1 Abstract

The SARS-CoV-2 papain-like (PL^{pro}) protease is essential for viral replication. We investigated 2 potential antiviral effects of hypericin relative to the well-known noncovalent PL^{pro} inhibitor 3 4 GRL-0617. Molecular dynamics and PELE Monte Carlo simulations highlight favourable binding of hypericin and GRL-0617 to the naphthalene binding pocket of PL^{pro}. Although not 5 6 potent as GRL-0617 (45.8 vs 1.6µM for protease activity, respectively), in vitro fluorogenic enzymatic assays with hypericin show concentration-dependent inhibition of both PL^{pro} 7 8 protease and deubiquitinating activities. Given its use in supplementations and the FDA 9 conditional approval of a synthetic version, further evaluation of hypericin as a potential SARS-CoV-2 antiviral is warranted. 10

11

12 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the highly transmissible 13 pathogen responsible for coronavirus disease 2019 (COVID-19) and the evolving pandemic 14 [1]. A number of SARS-CoV-2 variants of concern have been identified by the World Health 15 Organization (WHO), and the increased transmissibility or virulence of emerging variants 16 continues to be a challenge [2]. Upon entry into host cells, the single-stranded RNA genome 17 (positive-sense) is released into the cytoplasm and the polyproteins pp1a and pp1ab are 18 produced from the translation of the open reading frames (ORF1a and ORF1b) [3, 4]. The 19 polyproteins are cleaved by two cysteine proteases, the main protease (M^{pro}) and papain-like 20 protease (PL^{pro}), to form 16 non-structural proteins (nsps) [3, 4]. The M^{pro} is located at nsp5 21 and the PL^{pro} domain is encoded within nsp3 [3]. 22

Cysteine proteases play an essential role in the virus life cycle and have been identified as
 promising drug targets [5]. The SARS-CoV-2 PL^{pro} is comprised of an N-terminal ubiquitin-

like domain (Ubl), thumb domain, finger domain, and palm domain (Figure 1A). The protease
activity of PL^{pro} is coordinated by the conserved catalytic triad residues C111, H272, and D286
(Figure 1A) [6, 7]. The SARS-CoV-2 PL^{pro} recognises the P4-P1 consensus sequence LXGG
(X = any amino acid) and hydrolyses the peptide bond that is found between nsp1-nsp2, nsp2nsp3, and nsp3-nsp4 (P4-P1↓P1') [8]. This results in the release of nsp1, nsp2, and nsp3 [8].

The immunomodulating activities of the SARS-CoV-2 PL^{pro} are also being explored. 6 Ubiquitination is a posttranslational modification that regulates cellular pathways, including 7 immune responses to viral infections [9]. The C-terminus of ubiquitin and ubiquitin-like 8 proteins, which carries the LXGG motif, binds to target proteins by forming a covalent 9 isopeptide bond with the ε-amino group of lysine side chains [10]. Studies have demonstrated 10 that the SARS-CoV and SARS-CoV-2 PL^{pro} have deubiquitinating and deISGylating activities, 11 which result in the inhibition of the antiviral immune response [10, 11]. The SARS-CoV and 12 13 SARS-CoV-2 PL^{pro} preferentially target ubiquitin chains and interferon-stimulated gene 15 (ISG15), respectively [6, 10-12]. Furthermore, two ubiquitin binding sites (SUb1 and SUb2) 14 have been identified in PL^{pro} and the SUb2 region facilitates the binding of K48-diubiquitin or 15 16 -polyubiquitin and ISG15 [13]. In comparison to the SUb2 site, the active site and SUb1 site of the SARS-CoV and SARS-CoV-2 PL^{pro} exhibit high conservation at the amino acid level 17 18 [6].

Due to PL^{pro} being a multifunctional protein, it is an attractive target for therapeutic agents [14]. Covalent inhibitors of the SARS-CoV-2 PL^{pro}, such as VIR250 and VIR251, have predominantly been designed to modify the catalytic triad residue C111 through a Michael Addition reaction and form a covalent thioether bond [6]. Ebselen, an organoselenium drug, and its analogues have also been identified as covalent inhibitors of the SARS-CoV and SARS-CoV-2 PL^{pro} [15]. Moreover, noncovalent inhibitors have gained a significant amount of attention and this includes naphthalene-based compounds [16]. GRL-0617 was initially developed as a noncovalent inhibitor of the SARS-CoV PL^{pro} and has been found to inhibit the
SARS-CoV-2 PL^{pro} [11, 17]. The naphthalene-based inhibitor binds to the S3 and S4 subsites
and is positioned in a cleft that leads to the active site [7, 8, 11, 17, 18].

Using molecular docking and enzymatic assays, we previously identified hypericin as a 4 potential lead compound from a library of 300 ligands for the inhibition of the SARS-CoV-2 5 PL^{pro} [19, 20]. The naphthodianthrone hypericin is a secondary metabolite found in St. John's 6 Wort (Hypericum perforatum) and the broad pharmacological activities of this compound have 7 8 been reported [21]. Hypericin has also been identified as a potential inhibitor against the SARS-CoV-2 M^{pro} [22, 23]. The chemopreventative properties of synthetic hypericin (SGX-301) have 9 been of particular interest and the clinical development of SGX-301 as a photosensitising agent 10 for the treatment of cutaneous T-cell lymphoma is underway in the European Union and USA 11 [24]. 12

Here, our aim was to investigate the potential PL^{pro} inhibition activity of hypericin relative to the well-known noncovalent inhibitor GRL-0617. We performed comparative *in silico* allatom microsecond molecular dynamics and Protein Energy Landscape Exploration (PELE) Monte Carlo simulations to investigate the stability and interactions of hypericin and GRL-0617 with the PL^{pro} naphthalene binding pocket. Further, we performed *in vitro* PL^{pro} protease and deubiquitinase activity assays to determine the inhibition activity of hypericin in comparison to GRL-0617.

20

21 Materials and Methods

22 All-atom molecular dynamics simulations

1 GRL-0617, hypericin and its isomer were docked using the quantum-mechanics polarised ligand docking (QPLD) protocol of the Schrödinger suite [25, 26] to the naphthalene binding 2 site of SARS-CoV-2 PL^{pro} (PDB ID: 7JRN) [27] to serve as starting structures for simulations, 3 as previously described [20]. Briefly, a 20 x 20 x 20 Å receptor grid was centred around 4 residues surrounding the co-crystallised ligand. Using the QPLD docking protocol, initial 5 6 docking was carried out with the extra precision (XP) scoring function of Glide [28], and partial charges of the ligand were calculated using quantum mechanical methods with the 'accurate' 7 8 setting in Jaguar [29]. Subsequent re-docking was performed with XP docking mode, with final poses selected based on GlideScore. The docked GRL-0617 had an RMSD of 0.52 Å compared 9 to the crystal structure. SwissParam was used to generate ligand topologies [30]. 10

Molecular dynamics (MD) simulations using GROMACS 2018.2 software [31, 32] were 11 performed with the CHARMM27 force field [33, 34], as previously described [23]. The TIP3P 12 13 water model [35] was used to solvate the protein-ligand complexes in a dodecahedral box with a distance of 2.0 nm between protein atoms and the box edge. The system was neutralised with 14 15 sodium ions, and underwent energy minimisation using the steepest-descent gradient method. 16 Equilibration was performed with the canonical (NVT) ensembled followed by an isothermalisobaric ensemble (NPT) for 100 ps. A modified Berendsen thermostat [36] was used to 17 18 maintain a temperature of 310 K, and pressure at 1.0 bar the Parrinello-Rahman barostat [37]. The LINCS algorithm [38] was applied to constrain bond lengths, particle-mesh Ewald scheme 19 (PME) [39] was used to calculate long-range electrostatic forces (grid spacing 0.16 nm), and 20 cut-off ratios for Coulomb and van der Waals potentials were set at 1.2 nm. Production runs 21 were carried out for 1000 ns with a time-step of 2 fs. Additional simulations were performed 22 for 100 ns in triplicate. 23

Simulated trajectories were visualised and analysed using Visual Molecular Dynamics 1.9.3
[40] and PyMOL [41]. Analysis tools included within the GROMACS software package were

1 utilised, including gmx rms and gmx rmsf for calculation of RMSD and RMSF for the protein 2 backbone. Clusters of similar structures based on RMSD of the protein backbone were 3 calculated for the entire trajectory using gmx cluster, utilising the gromos clustering algorithm 4 as described by Daura et al. [42]. An RMSD cut-off of 0.2 nm was used to define two structures as neighbours to obtain approximately 32 clusters for each system. The central structure of 5 each cluster was written for analysis. The number of contacts between residues of PL^{pro} and 6 the ligands was calculated using gmx mindist with a threshold of 0.45 nm to define a contact 7 8 [31, 32]. This was calculated as an average number between the ligand and each residue 9 throughout the entire trajectory.

10

11 PELE Monte Carlo energy landscape explorations

12 Protein energy landscape exploration (PELE) analysis was performed as described previously [23, 43]. Briefly, binding sites for GRL-0617 and hypericin were identified on the SARS-CoV-13 2 PL^{pro} using an adaptive-PELE Monte Carlo (MC) search. This involves random placement 14 of fully solvated ligands with no direct contact with the protein (40 initial positions) to 15 undertake an unsupervised global search and local refinement of binding sites along the entire 16 17 protein surface [43]. The process involves approximately 256,000 PELE steps to provide 100 epochs, or rounds, of 10 Monte Carlo steps using 256 computing cores for global sampling of 18 combined large (\sim 3 Å) and short (\sim 1 Å) ligand translations [43]. 19

Following the global search, the best poses from local minima with lower interaction energy were used to define initial structures for local refinement. Local refinement was performed with shorter simulations involving smaller ligand translations and rotations; 10 epochs of 24 MC steps (20-30 computing cores per minima). The integrated PELE protein-ligand interaction energy was calculated for analysis by subtracting the receptor and ligand energies from the complex at a given geometry, using the OPLS-AA force with a generalised surface Born
 solvent model [43]. This produced unbiased binding sites which were discriminated among the
 GRL-0617 and hypericin ligands.

4

5 Fluorogenic PL^{pro} protease and deubiquitinase inhibition assays

To investigate the inhibitory activity of small molecules in vitro, proprietary PL^{pro} protease and 6 7 deubiquitinase assay kits, which contain the recombinant PL^{pro} and appropriate substrates, were utilised according to the manufacturer's protocols (BPS Bioscience, San Diego, CA, USA). 8 Hypericin (89%, HWI pharma services GmbH, Germany), was prepared as a 20mM stock and 9 stored at -80°C until use. Working stocks of hypericin were prepared by doubling dilution to 10 achieve final concentrations in the range of $1.5 - 200\mu$ M. The positive internal control GRL-11 0617 was used at final concentration of 100µM. Following incubation the fluorogenic substrate 12 (excitation wavelength = 360nm) was measured at 460nm using a CLARIOstar microplate 13 reader (BMG Labtech, Ortenberg, Germany), at gains of 1164 and 1460 for the protease and 14 15 deubiquitinase assays, respectively, to ensure that both background and test values were in an appropriate range for accurate detection. In both assays, the test inhibitors were assayed in 16 triplicate; six determinations were made for the background and nine for total PL^{pro} protease 17 and deubiquitinase activities and the GRL-0617 positive control. Absolute fluorescence 18 intensity values at 460 nm were measured, and % protease inhibition activity at 100µM 19 hypericin and GRL0617, and IC₅₀ values for hypericin were calculated. 20

21

22 **Results and Discussion**

23 Structural effects in response to ligand binding to the PL^{pro} naphthalene binding site

1 MD simulations were performed using previously identified [20] compounds GRL-0617, hypericin, and its isomer (Figure 1B) with trajectories spanning 1000 ns. Analysis of the PL^{pro} 2 3 trajectories show a jump in protein backbone RMSD approximately halfway through the simulation for the apo and GRL-0617-bound PL^{pro} (Figure 1C). The average RMSD of apo 4 PL^{pro} went from 0.20 to 0.55 nm at 544 ns. Similarly, the RMSD of GRL-0617-bound PL^{pro} 5 jumps from 0.20 to 0.50 nm at 520 ns. Hypericin-bound PL^{pro} briefly has an RMSD of 0.20 nm 6 for the first 15 ns before maintaining an average RMSD of 0.58 nm for the remaining trajectory. 7 Hypericin-isomer-bound PL^{pro} quickly reaches equilibrium, with the trajectory maintaining a 8 9 stable average RMSD of 0.22 nm after 1 ns. Triplicate 100 ns trajectories also showed that all systems reached equilibrium within 10 ns (Figure S1). The number of hydrogen bonds within 10 the protein were similar for all systems, with averages of 236 for apo, 233 for GRL-0617-11 bound, and 230 for hypericin and its isomer-bound PL^{pro} (Figure S2). 12

13 Similar trends are observed in cluster analysis, which show two distinct conformations of PL^{pro} that dominate throughout the trajectory (Figure 2). Both the apo-PL^{pro} and GRL-0617-bound 14 PL^{pro} adopt a similar conformation for the first half of the trajectory, with frames corresponding 15 to cluster 1 structures for 41.9% and 44.5% of the trajectory in apo and GRL-0617-bound 16 systems respectively. For the second half of the trajectory, the cluster 2 structure is dominant, 17 with 40.4% of apo and 44.0% of GRL-0617-bound PL^{pro} frames of the trajectory corresponding 18 to this conformation. The hypericin analogue-bound PL^{pro} systems adopt a single conformation 19 for the majority of the trajectory. Hypericin-bound PL^{pro} maintains the equivalent of apo and 20 GRL-0617-bound cluster 2 conformation for 78.4% of the trajectory. Conversely, hypericin-21 isomer-bound PL^{pro} maintains a conformation corresponding to the cluster 1 structures for apo 22 and GRL-0617 for 82.1% of the trajectory. It is noted that this conformation is close to the 23 crystal structure. The apo cluster 1 structure has an RMSD of 1.55 Å compared to the crystal 24

structure, whereas the cluster 2 structure has an RMSD of 5.45 Å (Table S1). The differences
 between the structures can be attributed to the Ubl-domain (Figure S3).

RMSF analysis indicates the fluctuation in RMSD may be attributed to the N-terminal Ubl 3 domain of PL^{pro} (Figure 1D), which demonstrated the greatest flexibility in the protein. All 4 ligands are shown to suppress RMSF, with hypericin and its isomer more effective than GRL-5 0617, especially at the Ubl domain (Figure 1D). This is likely due to hypericin analogue-bound 6 PL^{pro} systems remaining in a single cluster conformation for ~80% of the trajectory (Figure 2). 7 8 The blocking loop 2 (BL2, GNYQCGH) region is flexible, with these residues having a higher RMSF for hypericin-bound compared to the isomer and GRL-0617-bound PL^{pro}. In particular, 9 Y268 had an RMSF of 0.54 nm in apo and 0.44 nm in hypericin-bound PL^{pro}, compared to 10 values of 0.24 and 0.26 nm in GRL-0617 and hypericin-isomer-bound PL^{pro}, respectively 11 (Figure 1D). 12

13 Stability of compounds bound to the PL^{pro} active site

Visual analysis of trajectories indicates a largely stable enzyme with contraction and expansion 14 of the Ubl domain corresponding to conformational changes described by changes in RMSD 15 and cluster analysis (Movies S1 to S4). GRL-0617 stays firmly bound to the naphthalene 16 binding site throughout the trajectory (Movie S2), reinforcing its validity as a positive control. 17 Contacts analysis demonstrates the proximity of the ligand with key residues in the naphthalene 18 binding pocket (Figure 3), particularly Y268 which had an average of 107 contacts with GRL-19 0617 throughout the trajectory. Also prominent was D164 (65 contacts) and P248 (69 contacts). 20 21 Analysis of hydrogen bonds indicates that GRL-0617 demonstrated a greater average number of hydrogen bonds were formed with PL^{pro}, forming an average of 2.34 hydrogen bonds with 22 23 PL^{pro}, compared with values of 0.76 and 0.83 for hypericin and its isomer (Figure S2). Similarly, the isomer of hypericin also remained bound to the naphthalene binding pocket for 24

the duration of the trajectory (Movie S4), forming contacts with similar residues. Y268 is the most frequent residue, forming an average of 139 contacts with the hypericin isomer throughout the trajectory. Contacts were also formed between the hypericin isomer and residues located deeper within the binding site, including R166 (65 contacts) and M208 (16 contacts) (Figure 3).

While ligand unbinding was initially observed, hypericin re-attaches to the enzyme at 6 approximately 150 ns into the trajectory at the active site of the enzyme in proximity to the 7 8 catalytic triad residues (Movie S3). This is also illustrated in Figure S4 depicting the distance between ligands and the catalytic triad residues throughout the trajectory. Hypericin initially 9 deviates from the naphthalene binding site before binding to the active site of PL^{pro}, with an 10 average distance of 0.95 nm from the catalytic triad residues after 150 ns. This is closer than 11 GRL-0617 and the hypericin isomer, which were 1.38 and 1.61 nm from the catalytic triad 12 13 residues, respectively (Figure S4). While modest, contacts are observed between hypericin and the catalytic C111, H272 and D286 residues (Figure 3). The most frequent residue in 14 15 contact with hypericin throughout the trajectory was W106 (127 contacts). Although hypericin 16 was binding to a different site to its isomer and GRL-0617, Y268 is still among the most prominent residues, forming an average of 96 contacts with hypericin. This residue is located 17 18 within the BL2 loop, which ordinarily caps the naphthalene binding site [7], but in this case is flipped downwards to an open conformation, accommodating binding of hypericin with the 19 catalytic residues in the active site. This is supported by the higher RMSF of Y268 (Figure 1D) 20 for hypericin-bound PL^{pro}, as well as the RMSD observed for BL2 loop residues (Figure S5). 21 22 The RMSD of BL2 loop residues remain relatively stable for GRL-0617 and hypericin isomerbound PL^{pro}, with average values of 0.25 and 0.42 nm for the entire trajectory, respectively. 23 The ligand-free PL^{pro} shows the BL2 loop flipping open and closed for the first 400 ns, before 24 remaining closed to cap the naphthalene binding site for the remainder of the trajectory with 25

an average RMSD of 0.22 nm (Figure S5). This may indicate that as well as capping the
naphthalene binding site, the BL2 loop functions to secure ligand binding to the active site.
This suggests a ligand-mediated induced-fit mechanism which prevents the binding of natural
LXGG motif-containing substrates, resulting in the inhibition of both the protease and
deubiquitinase activities of PL^{pro} [7, 17, 44].

6

7 PELE Monte Carlo simulations highlight ligand interactions with PL^{pro} binding pockets

Adaptive-PELE Monte Carlo simulations were performed with GRL-0617 and hypericin to 8 identify binding modes on PL^{pro}. The plot in Figure 4 depicts all the interaction energies for 9 poses explored by PELE against the RMSD to the initial crystal structure of GRL-0617. Only 10 using the crystal structure as analysis, the best protein-ligand poses with the lowest interaction 11 energies were located in the naphthalene binding site (Figure 4A). These poses are at 1 Å and 12 3 Å from the crystal structure, producing binding affinities of -38 and -39 kcal/mol, 13 respectively, with residue interactions similar to that of the co-crystallised GRL-0617 (Figure 14 4C). This shows that PELE reproduces the crystal structure. 15

16 Hypericin was also found to bind to the naphthalene binding site, with pose 1 (Figure 5) producing a binding affinity of -47 kcal/mol. As well as the naphthalene binding pocket, 17 additional binding sites were identified for hypericin. Notably, pose 2 (Figure 5) was near the 18 catalytic triad residues, positioned in a similar manner to hypericin following MD simulation 19 20 (Figure 3, Movie S3). This pose had a binding affinity of -46 kcal/mol, forming hydrogen bonds 21 with N109, C270, L274, and the catalytic D286. Additional poses were identified with 22 comparable binding energies: pose 3 between the palm and thumb domains (-53 kcal/mol) and 23 pose 5 located on the Ubl-like domain (-48 kcal/mol). Pose 4 (-51 kcal/mol) was in the zinc 24 finger domain, forming a hydrogen bond with the zinc-coordinating residue C189 (Figure 5C).

This residue has been targeted for inhibition with other small molecules to disrupt zinc binding
in SARS-CoV-2 PL^{pro} [45]. Overall these findings indicate that hypericin preferentially binds
to the canonical naphthalene binding and active sites associated with inhibition of the PL^{pro},
and also may possess zinc-modifying properties [45].

5

6 *Hypericin inhibits the SARS-CoV-2 PL^{pro} protease and deubiquitinase activities in vitro*

7 We have previously investigated the in vitro PL^{pro} protease and deubiquitinase inhibitory activities of small molecules including those of hypericin [19, 20]. Here, our findings confirm 8 the concentration-dependent inhibition of PL^{pro} protease and deubiquitinase activities of 9 hypericin (Figure 6). At a concentration of 100µM, hypericin possessed inhibition activities 10 $(97.9 \pm 1.8 \text{ and } 91.4 \pm 3.2 \text{ for protease and deubiquitinase, respectively})$, that were analogous 11 12 to the internal positive control GRL-0617 (96.9 \pm 1.6µM and 88.4 \pm 4.9µM; Table 1). However, the IC₅₀ values were calculated to be $45.8 \pm 7.2 \mu$ M and $20.3 \pm 8.3 \mu$ M for the PL^{pro} protease 13 and deubiquitinase inhibition activities of hypericin, highlighting decreased potency compared 14 to GRL-0617 (1.6µM and 1.7µM; Table 1). Typical plasma concentrations of hypericin range 15 from 36 – 180 nM following consumption of LI 160 hypericum extracts containing 1.09 – 4.36 16 mg hypericin [46]. Standard over the counter formulations of St John's wort contain 17 approximately 1 mg of hypericin. It is noteworthy that it has been used in a variety of human 18 clinical trials, including in the context of premenstrual syndrome, nonmelanoma skin cancer, 19 and hepatitis C virus infection [47-49]. Furthermore, concentration-dependent uptake of 20 21 hypericin has been observed in Caco-2 cell assays [50]. Nevertheless, the inhibition activities are within biologically relevant ranges and the findings are encouraging. 22

23

1 Conclusion

Overall, microsecond molecular dynamics simulations highlight the stability of GRL-0617 and 2 hypericin in the naphthalene binding pocket of the SARS-CoV-2 PL^{pro}. Similarly, PELE 3 Monte Carlo simulations indicate favourable energies associated with interactions of the small 4 molecules in the naphthalene binding site. Finally, enzymatic assays *in vitro* confirm the 5 potency with respect to inhibition of PL^{pro} protease and deubiquitinase activities of the well-6 known inhibitor GRL-0617. In comparison, although not as potent, hypericin also inhibits 7 8 PL^{pro} protease and deubiquitinase activities with IC₅₀ values in the biologically relevant micromolar range. When considering potential clinical utility, the long history of use of 9 10 hypericin in supplementations and the conditional Food and Drug Administration (FDA) approval of a synthetic version (designated SGX 301), are encouraging, and highlight the 11 importance of further evaluation in appropriate antiviral models. 12

13

14 Author contributions statement

TCK, AH, and VG conceptualized the aims and methodology, were involved in supervision, and production of the first draft of the manuscript. VG performed data analysis and curated data. KV performed and analysed the *in vitro* protease inhibition assay. JJL and EP were involved in data analysis and curation, and in production of the first draft of the manuscript.

20

21 Acknowledgements

22 We would like to acknowledge intellectual and financial support by McCord Research (Iowa,

23 USA). JJL is supported by an Australian Government Research Training Program Scholarship.

We are indebted to Alfonso Perez Escudero and the team at Crowdfight COVID-19 for 1 2 enabling access to supercomputing facilities, and to Matthew Gasperetti and the team at Hypernet Labs; Galileo, for enabling cloud computing for this project. We thank the National 3 4 Computing Infrastructure (NCI), and the Pawsey Supercomputing Centre in Australia (funded by the Australian Government). Further, we thank the Spartan High Performance Computing 5 service (University of Melbourne), and the Partnership for Advanced Computing in Europe 6 7 (PRACE) for awarding access to Piz Daint, hosted at the Swiss National Supercomputing Centre (CSCS), Switzerland. 8

9

10 **Conflict of interest**

11 Epigenomic Medicine Program (TCK) is supported financially by McCord Research (Iowa,

12 USA), which may have a financial interest in dietary compounds described in this work.

13 However, there is no conflict of interest with respect to the inhibition of the SARS-CoV-2

14 papain-like protease. The remaining co-authors also have no conflicts of interest.

15

16 **References**

Gorbalenya, A.E., et al., *The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.* Nature Microbiology,
 2020. 5(4): p. 536-544.

- 20 2. Krause, P.R., et al., *SARS-CoV-2 Variants and Vaccines*. New England Journal of
 21 Medicine, 2021. 385(2): p. 179-186.
- 22 3. V'kovski, P., et al., *Coronavirus biology and replication: implications for SARS-CoV-*23 2. Nature Reviews Microbiology, 2021. 19(3): p. 155-170.
- Khailany, R.A., M. Safdar, and M. Ozaslan, *Genomic characterization of a novel SARS- CoV-2.* Gene Reports, 2020. 19: p. 100682.
- Verma, S., R. Dixit, and K.C. Pandey, *Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets*. 2016. 7(107).
- 28 6. Rut, W., et al., Activity profiling and crystal structures of inhibitor-bound SARS-CoV-
- 2 papain-like protease: A framework for anti-COVID-19 drug design. Science
 30 Advances, 2020. 6(42): p. eabd4596.

7. Gao, X., et al., Crystal structure of SARS-CoV-2 papain-like protease. Acta 1 Pharmaceutica Sinica B, 2021. 11(1): p. 237-245. 2 Osipiuk, J., et al., Structure of papain-like protease from SARS-CoV-2 and its 8. 3 4 complexes with non-covalent inhibitors. Nature Communications, 2021. 12(1): p. 743. 5 9. Gu, H. and B. Jan Fada, Specificity in Ubiquitination Triggered by Virus Infection. International journal of molecular sciences, 2020. 21(11): p. 4088. 6 7 10. Ratia, K., et al., Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease. PLOS Pathogens, 2014. 10(5): p. 8 e1004113. 9 10 11. Shin, D., et al., Papain-like protease regulates SARS-CoV-2 viral spread and innate *immunity*. Nature, 2020. **587**(7835): p. 657-662. 11 12. Drag, M., et al., Positional-scanning fluorigenic substrate libraries reveal unexpected 12 13 specificity determinants of DUBs (deubiquitinating enzymes). The Biochemical journal, 2008. 415(3): p. 367-375. 14 13. Klemm, T., et al., Mechanism and inhibition of the papain-like protease, PLpro, of 15 SARS-CoV-2. The EMBO Journal, 2020. 39(18): p. e106275. 16 17 14. McClain, C.B. and N. Vabret, SARS-CoV-2: the many pros of targeting PLpro. Signal Transduction and Targeted Therapy, 2020. 5(1): p. 223. 18 Weglarz-Tomczak, E., et al., Identification of ebselen and its analogues as potent 19 15. 20 covalent inhibitors of papain-like protease from SARS-CoV-2. Scientific Reports, 2021. **11**(1): p. 3640. 21 Delre, P., et al., Repurposing Known Drugs as Covalent and Non-covalent Inhibitors 22 16. 23 of the SARS-CoV-2 Papain-Like Protease. 2020. 8(1032). 17. Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors 24 blocks SARS virus replication. Proceedings of the National Academy of Sciences of the 25 26 United States of America, 2008. 105(42): p. 16119-16124. 27 18. Fu, Z., et al., The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nature communications, 2021. 12(1): p. 488-488. 28 Pitsillou, E., et al., Identification of Small Molecule Inhibitors of the Deubiquitinating 29 19. Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies 30 and in vitro Enzymatic Activity Assay. Frontiers in chemistry, 2020. 8: p. 623971-31 623971. 32 20. Pitsillou, E., et al., Interaction of small molecules with the SARS-CoV-2 papain-like 33 protease: In silico studies and in vitro validation of protease activity inhibition using 34 an enzymatic inhibition assay. J Mol Graph Model, 2021. 104: p. 107851. 35 36 21. Jendželovská, Z., et al., Hypericin in the Light and in the Dark: Two Sides of the Same 37 Coin. 2016. 7(560). Loschwitz, J., et al., Novel inhibitors of the main protease enzyme of SARS-CoV-2 38 22. 39 identified via molecular dynamics simulation-guided in vitro assay. Bioorganic 40 Chemistry, 2021. 111: p. 104862. 23. Liang, J., et al., Small molecule interactions with the SARS-CoV-2 main protease: In 41 silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and 42 determination of in vitro activity inhibition. Journal of Molecular Graphics and 43 Modelling, 2022. 110: p. 108050. 44 45 24. Scarisbrick, J.J., M. Bagot, and P.L. Ortiz-Romero, The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell 46 lymphoma. British journal of haematology, 2021. 192(4): p. 683-696. 47 48 25. Schrödinger, Schrödinger Release 2020-2: QM-Polarized Ligand Docking protocol; Glide, Schrödinger, LLC, New York, NY, 2016; Jaguar, Schrödinger, LLC, New York, 49 NY, 2016; QSite, Schrödinger, LLC, New York, NY, 2020. 2020. 50

- Cho, A.E., et al., Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. Journal of computational chemistry, 2005. 26(9): p. 915-931.
- 4 27. Ma, C., et al., *Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a*5 *Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay.*6 ACS Cent Sci, 2021. 7(7): p. 1245-1260.
- Friesner, R.A., et al., *Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein–Ligand Complexes.* Journal of Medicinal
 Chemistry, 2006. 49(21): p. 6177-6196.
- Bochevarov, A.D., et al., Jaguar: A high-performance quantum chemistry software
 program with strengths in life and materials sciences. International Journal of Quantum
 Chemistry, 2013. 113(18): p. 2110-2142.
- 30. Zoete, V., et al., SwissParam: a fast force field generation tool for small organic
 molecules. J Comput Chem, 2011. 32(11): p. 2359-68.
- Berendsen, H.J.C., D. van der Spoel, and R. van Drunen, *GROMACS: A message- passing parallel molecular dynamics implementation*. Computer Physics
 Communications, 1995. 91(1): p. 43-56.
- Abraham, M.J., et al., *GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers*. SoftwareX, 2015. 1-2: p. 19 25.
- 33. Bjelkmar, P., et al., *Implementation of the CHARMM Force Field in GROMACS: Analysis of Protein Stability Effects from Correction Maps, Virtual Interaction Sites, and Water Models.* Journal of Chemical Theory and Computation, 2010. 6(2): p. 459466.
- 34. Vanommeslaeghe, K., et al., *CHARMM General Force Field (CGenFF): A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.* Journal of computational chemistry, 2010. **31**(4): p. 671-690.
- 35. Jorgensen, W.L., et al., *Comparison of simple potential functions for simulating liquid water.* The Journal of chemical physics, 1983. **79**(2): p. 926-935.
- 30 36. Berendsen, H.J.C., et al., *Molecular dynamics with coupling to an external bath.* The
 31 Journal of Chemical Physics, 1984. 81(8): p. 3684-3690.
- 32 37. Parrinello, M. and A. Rahman, *Crystal Structure and Pair Potentials: A Molecular-* 33 *Dynamics Study*. Physical Review Letters, 1980. 45(14): p. 1196-1199.
- 34 38. Hess, B., et al., *LINCS: a linear constraint solver for molecular simulations*. Journal of
 35 computational chemistry, 1997. 18(12): p. 1463-1472.
- 36 39. Darden, T., D. York, and L. Pedersen, *Particle mesh Ewald: An N·log(N) method for* 37 *Ewald sums in large systems*. The Journal of Chemical Physics, 1993. 98(12): p. 10089 38 10092.
- 40. Humphrey, W., A. Dalke, and K. Schulten, *VMD: visual molecular dynamics*. J Mol
 Graph, 1996. 14(1): p. 33-8, 27-8.
- 41 41. Schrodinger, LLC, *The PyMOL Molecular Graphics System, Version 1.8.* 2015.
- 42 42. Daura, X., et al., *Peptide Folding: When Simulation Meets Experiment*. Angewandte
 43 Chemie International Edition, 1999. 38(1-2): p. 236-240.
- 44 43. Lecina, D., J.F. Gilabert, and V. Guallar, *Adaptive simulations, towards interactive*45 *protein-ligand modeling.* Scientific Reports, 2017. 7(1): p. 8466.
- 46 44. Bosken, Y.K., et al., *Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein*47 *Binding in SARS-CoV-2 Papain-Like Protease*. 2020. 7(174).
- 48 45. Sargsyan, K., et al., *Multi-targeting of functional cysteines in multiple conserved SARS-*49 *CoV-2 domains by clinically safe Zn-ejectors.* Chemical Science, 2020. 11(36): p.
 50 9904-9909.

46. Brockmöller, J., et al., *Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans.* Pharmacopsychiatry, 1997. **30 Suppl 2**: p. 94-101.

- 47. Jacobson, J.M., et al., *Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.*Antimicrobial agents and chemotherapy, 2001. 45(2): p. 517-524.
- 6 48. Canning, S., et al., *The Efficacy of Hypericum perforatum (St John's Wort) for the* 7 *Treatment of Premenstrual Syndrome*. CNS Drugs, 2010. 24(3): p. 207-225.
- 8 49. Kacerovská, D., et al., *Photodynamic Therapy of Nonmelanoma Skin Cancer with*9 *Topical Hypericum perforatum Extract—A Pilot Study*. Photochemistry and
 10 Photobiology, 2008. 84(3): p. 779-785.
- So. Verjee, S., et al., Permeation characteristics of hypericin across Caco-2 monolayers in the presence of single flavonoids, defined flavonoid mixtures or Hypericum extract matrix. J Pharm Pharmacol, 2019. **71**(1): p. 58-69.
- 14

15 Figure legends

Figure 1: Classical MD simulation of ligands bound with SARS-CoV-2 PL^{pro}. A) The 16 SARS-CoV-2 PL^{pro} is composed of four main domains; the Ubl, thumb, fingers, and palm 17 18 domain. PL^{pro} also contains four subsites highlighted in surface representation: S1 and S2 for ubiquitin- and ISG16-binding, and naphthalene-based inhibitors bind in the S3 and S4 subsites. 19 20 Protease activity is mediated by catalytic triad residues in the active site. B) Chemical structures of GRL-0617, hypericin, and its isomer. C) MD simulations were performed for 1000 ns. Root 21 mean square deviation (RMSD) of PL^{pro} protein backbone. D) Root mean square fluctuation 22 (RMSF) of PL^{pro} backbone throughout the trajectory. Data for the apo PL^{pro} is shown in grey, 23 GRL-0617-bound in red, hypericin-bound in blue, and hypericin-isomer-bound in green. 24

25 Figure 2: Cluster analysis of 1000 ns MD simulation trajectories of SARS-CoV-2 PL^{pro}

complexes. A) Heatmap depicting cluster number throughout the trajectory. The top six
clusters from 100,000 frames are depicted for each system. B) Structures from different
systems similar to cluster 1 of apo PL^{pro}, with the proportion of frames shown as a percentage.
C) Structures from different systems similar to cluster 2 of apo PL^{pro}, with the proportion of

frames shown as a percentage. Structures for the apo PL^{pro} are shown in grey, GRL-0617-bound
in red, hypericin-bound in blue, and hypericin-isomer-bound in green.

3 Figure 3: Number of contacts between residues of SARS-CoV-2 PL^{pro} and bound ligands.

The average number of contacts throughout the trajectory between all residues of PL^{pro} and
bound ligands was calculated for A) GRL-0617, B) hypericin, and C) the isomer of hypericin.
Residue interactions are shown for the final frame of the trajectory. Data for the GRL-0617bound PL^{pro} is shown in red, hypericin-bound in blue, and hypericin-isomer-bound in green.

Figure 4: PELE binding site search of GRL-0617 on SARS-CoV-2 PL^{pro}. A) Interaction energy plot vs RMSD distance to the crystallographic position GRL-0617 in the naphthalene binding site. The global search is shown in dark blue and structures of the first epoch are shown in cyan, showing that initial positions are not close to the crystal structure. B) The two best poses following global refinement of GRL-0617 are numbered. C) Residue interactions for cocrystallised GRL-0617, and poses identified following PELE analysis. Hydrogen bonds are depicted as dashed blue lines.

Figure 5: PELE binding site search of hypericin on SARS-CoV-2 PL^{pro}. A) Interaction energy plot vs RMSD distance to initial position of hypericin in the naphthalene binding site. The global search is shown in dark blue and locally refined poses are shown in cyan. B) The best five poses following local refinement of hypericin are numbered. C) Residue interactions for poses identified following PELE analysis. Hydrogen bonds are depicted as dashed blue lines.

Figure 6: Inhibition of the SARS-CoV-2 PL^{pro} protease and deubiquitinase activities by hypericin. The protease and deubiquitinase inhibition activities of hypericin were determined using commercial PL^{pro} assay kits, consisting of a proprietary fluorogenic substrate at an emission wavelength of 460nm (BPS Bioscience, San Diego, CA, USA). Hypericin (0.2 μM

to 200 μM concentration range was investigated), resulted in a concentration-dependent
inhibition of both protease (A), and deubiquitinase (B) activities. Average values ± SEM from
triplicate determinations are shown. The average background (n=6), total PL^{pro} protease and
deubiquitinase activities (n=9), and inhibition by the positive control GRL-0617 at 100μM
(n=9), are highlighted (horizontal dotted lines).

6 Table 1: Inhibition of PL^{pro} protease and deubiquitinase activities by GRL-0617 and

- 7 hypericin. Percentage inhibition at a ligand concentration of 100µM and IC₅₀ values from *in*
- 8 *vitro* fluorogenic PL^{pro} protease and deubiquitinase assays.
- 9
- 10

1 Supplementary Materials

Figure S1: Average RMSD (A) and RMSF (B) SARS-Cov-2 PL^{pro} backbone 100 ns
trajectories in triplicate. Data for apo PL^{pro} is shown in grey, GRL-0617-bound in red,
hypericin-bound in blue, and hypericin-isomer-bound PL^{pro} in green.

5 **Figure S2:** Number of hydrogen bonds for SARS-CoV-2 PL^{pro} protein bound with ligands (A)

6 and protein-ligand (B), shown as mean \pm SD over a 1000 ns trajectory.

Figure S3: Per-residue RMSD of backbone comparison between SARS-CoV-2 PL^{pro} cluster
structures. A) Comparison between cluster 1 and cluster 2 structures for apo- and GRL-0617bound PL^{pro}. B) Comparison to cluster 1 structure of apo-PL^{pro} for GRL-0617- and hypericinisomer-bound PL^{pro} cluster 1. C) Comparison to cluster 2 structure of apo-PL^{pro} for GRL-0617
cluster 2 and hypericin-bound PL^{pro} cluster 1. RMSD for apo-PL^{pro} is shown in grey, GRL0617- in red, hypericin isomer- in green, and hypericin-bound PL^{pro} in blue.

Figure S4: Distance between the centre of mass of SARS-COV-2 PL^{pro} catalytic triad residues
(C111, H272, D286) and bound ligands GRL-0617 (red), hypericin (blue) and its isomer
(green) throughout the simulation.

Figure S5: RMSD of blocking loop 2 residues (GNYQCGH) of SARS-CoV-2 PL^{pro} over 1000
ns. Data for apo PL^{pro} is shown in grey, GRL-0617-bound in red, hypericin-bound in blue, and
hypericin-isomer-bound PL^{pro} in green.

Table S1: RMSD alignment in angstroms (Å) of SARS-CoV-2 PL^{pro} backbone between
different cluster structures, with a cut-off of 2.0 Å to define a cluster

21 Movie S1: 1000 ns trajectory of the apo form of SARS-CoV-2 PL^{pro}

22 Movie S2: 1000 ns trajectory of GRL-0617 bound to SARS-CoV-2 PL^{pro}

20

- 1 Movie S3: 1000 ns trajectory of hypericin bound to SARS-CoV-2 PL^{pro}
- 2 Movie S4: 1000 ns trajectory of hypericin isomer bound to SARS-CoV-2 PL^{pro}

Table 1: Inhibition of PL^{pro} protease and deubiquitinase activities by GRL-0617 and

hypericin. Percentage inhibition at a ligand concentration of 100μ M and IC₅₀ values from *in vitro* fluorogenic PL^{pro} protease and deubiquitinase assays.

	Protease Activity		Deubiquitinase activity	
	IC50*	% Inhibition	IC50*	% Inhibition
		(100µM)		(100µM)
GRL-0617	1.6	96.9 ± 1.6	1.7	88.4 ± 4.9
Hypericin	45.8 ± 7.2	97.9 ± 1.8	20.3 ± 8.3	91.4 ± 3.2

* IC₅₀ values for GRL0617 according to assay manufacturer (BPS Bioscience, San Diego, CA, USA). Experimental average \pm SEM indicated for hypericin (IC₅₀), and % inhibition at 100 μ M ligand concentration for GRL-0617 and hypericin.

Figure 1: Classical MD simulation of ligands bound with SARS-CoV-2 PLpro. A) The SARS-CoV-2 PLpro is composed of four main domains; the Ubl, thumb, fingers, and




Figure 2: Cluster analysis of 1000 ns MD simulation trajectories of SARS-CoV-2 PLpro complexes.

